Molecular Devices to attend European Lab Automation
Product News May 03, 2012
ImageXpress® Micro XL is an invaluable tool for pinpointing mechanisms of action in the research or treatment of cancer, neurological disorders, viral infection, haemophilia, and premature aging. Regardless of resolution, and thanks to its laser auto focusing capabilities, brightfield imaging option and environmentally controlled chamber, the ImageXpress® Micro XL System offers researchers the benefit of imaging three times the sample area to deliver statistically relevant results in a third of the time. Whether searching for rare events or investigating multifaceted cell signalling pathways, the ImageXpress® Micro XL offers three times the data points per image to decrease the time to perform cellular- and high-resolution screens. This easily enables users to measure parameters such as cell cycle and apoptosis, the formation of micronuclei, neurite outgrowth, angiogenesis, intracellular translocation or endocytosis. For each assay, biological phenotypes can be automatically identified, segmented, and analyzed using a validated software module to generate accurate results for rapid screening.
The SpectraMax® Paradigm® Multi-Mode Microplate Detection Platform is the only user upgradeable microplate reader on the market that allows for real-time system configuration by the user in less than two minutes. This revolution in modularity allows you to read what you want, when you want without compromising your biology. Although your detection needs may change, your equipment can stay the same simply by adding a new detection cartridge.
We will have two customer presentations this year at European Lab Automation. Dr. Johnny Kim, Research Group Leader at Max-Planck-Institute for Heart and Lung Research, Germany will be presenting, “Identifying factors linked to self-renewal and differentiation of primary muscle stem cells: an integrative approach of mass spectrometry and high-throughput RNAi screening”. The second customer presentation is by Carsten Wenzel who is currently studying a Ph.D at Bayer Healtchare, Germany in the field of 3D based screening approach and high content analysis. He will be presenting, “3D Tumor Spheroids for Drug Discovery in Oncology”.